Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.

Multiple sclerosis (Houndmills, Basingstoke, England) - 1 Jul 2016

Longbrake E E, Ramsbottom M J, Cantoni C, Ghezzi L, Cross A H, Piccio L

Abstract excerpt

BACKGROUND: Dimethyl fumarate (DMF) alters the phenotype of circulating immune cells and causes lymphopenia in a subpopulation of treated multiple sclerosis (MS) patients. OBJECTIVE: To phenotypically characterize circulating leukocytes in DMF-treated MS patients. METHODS: Cross-sectional observational comparisons of peripheral blood from DMF-treated MS patients (n = 17 lymphopenic and n = 24 non-lymphopenic),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Immunologic Memory

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Immunosuppressive Agents

Share to Lymphocyte Count

Share to Lymphopenia

Share to Multiple Sclerosis

Share to T-Lymphocytes, Regulatory

Source

Open in PubMed Open full text

Identifiers

PMID: 26459150
DOI: 10.1177/1352458515608961
PMCID: PMC4829494

Genes

CCR6
CXCR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.PMID 26459150Read ↗

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosisSemantic proximity Read ↗

Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple SclerosisSemantic proximity Read ↗

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.Semantic proximity Read ↗

Low memory T cells blood counts and high naïve regulatory T cells percentage at relapsing remitting multiple sclerosis diagnosisSemantic proximity Read ↗

Real-world Safety and Efficacy of Dimethyl Fumarate in Relapse-Remitting Multiple Sclerosis Patients: A Regional Cohort Report of the Iranian PatientsSemantic proximity Read ↗

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.Semantic proximity Read ↗

Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.Semantic proximity Read ↗

Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments.Semantic proximity Read ↗

Altered regulatory T‐cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosisSemantic proximity Read ↗

Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literatureSemantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.